Purpose This multicenter, randomized, open-label, phase III trial compared the efficacy and
safety of decitabine with treatment choice (TC) in older patients with newly diagnosed acute …

Purpose Older patients with acute myeloid leukemia (AML) have limited treatment options
because of the lack of effectiveness and the toxicity of available therapies. We investigated …

The majority of patients with acute myeloid leukemia (AML) are elderly and have a poor
prognosis despite induction therapy. Decitabine, a DNA-hypomethylating agent that induces …

Background Hypomethylating agents, such as decitabine, are the standard of care for older
patients with newly diagnosed acute myeloid leukaemia. Single-arm studies have …

Elderly patients with acute myeloid leukemia (AML) have limited treatment options
concerned about their overall fitness and potential treatment related mortality. Although a …

Background The treatment of acute myeloid leukemia of older, medically non-fit patients still
poses a highly unmet clinical need, and only few large, prospective studies have been …

Abstract Treatment options for older patients with acute myeloid leukemia (AML) and for
patients with relapsed/refractory AML are limited, and outcomes are poor. Decitabine, a …

Background Front-line therapy for elderly or unfit patients with acute myeloid leukaemia
(AML) remains unsatisfactory with poor outcomes and excessive toxicity. We studied a new …

In this prospective phase 2 clinical trial conducted by Cancer and Leukemia Group B
(CALGB, now the Alliance), we studied decitabine as maintenance therapy for younger …

PURPOSE DNA-hypomethylating agents are studied in combination with other epigenetic
drugs, such as histone deacetylase inhibitors or differentiation inducers (eg, retinoids), in …